ADARx Pharmaceuticals, Inc. — Form 4
Filed September 30, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 78/100
What the filing says
Director ORBIMED ADVISORS LLC (ADRX) bought 24.2M shares (~$16.1M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
Tradability signal
NO TRADE
No trade: positive news with only +3.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=139). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $19.94 ▲ 0.00% | at our read · unknown $19.94 | +10 min · unknown $20.31 ▲ 1.86% | +30 min · unknown $20.00 ▲ 0.33% | +1 hr · unknown $20.26 ▲ 1.60% | +4 hrs · unknown $19.89 ▼ 0.25% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.